linjc16/ctgov huggingface dataset:
The Study of Ocular Hemodynamics With Glaucoma Progression

Study Overview
=================
Brief Summary
-----------------
To determine the relationships between ocular hemodynamics and glaucomatous optic neuropathy progression.

Detailed Description
-----------------
To determine whether baseline ocular blood flow values are predictive of glaucomatous progression as determined by visual field analysis. To determine how changes in ocular blood flow are related to visual field progression. To determine how changes in ocular blood flow are related to changes in optic nerve structure and topographic change over time.

Official Title
-----------------
The Study of Ocular Hemodynamics With Glaucoma Progression

Conditions
-----------------
Glaucoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will meet all of the following inclusion criteria to enter the study: Age: 30 years or older. Diagnosis: confirmed open-angle glaucoma in at least one eye: glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry glaucomatous optic disc cupping agreement between two baseline exams for reliability Best corrected visual acuity at least 20/60 in at least one eye. Prior Humphrey visual fields demonstrate acceptable reliability standards (see below). Exclusion Criteria: Extensive Humphrey visual field damage consisting of either a mean deviation (MD) < -15 decibels or a clinically determined threat to fixation in both hemifields. Evidence of exfoliation or pigment dispersion. History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis). History or signs of intraocular trauma. Severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment. Any abnormality preventing reliable applanation tonometry. Current use of any ophthalmic or systemic steroid which may interfere with this investigation. Cataract surgery within the past year. Resting pulse < 50 beats per minute. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glaucoma patients<br>Glaucoma patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular Blood Flow | per visit | various | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Blood Flow, Progression
NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors were found to decrease in the frontal lobe and hippocampus of mild cognitive impairment. This study is a randomized, double-blind, placebo-controlled drug trial. All subjects will be allocated randomly to 2 groups: (1) NMDA-enhancer: DAOIB group (starting dose: 250-500 mg/d); (2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy than placebo for cognitive function in patients with mild cognitive impairment.

Conditions
-----------------
Mild Cognitive Impairment

Intervention / Treatment
-----------------
* Drug: DAOIB
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of mild cognitive impairment MMSE between 17-26 CDR 0.5 Exclusion Criteria: Hachinski Ischemic Score > 4 Substance abuse/dependence Parkinson disease, epilepsy, dementia with psychotic features Major depressive disorder Major physical illnesses Severe visual or hearing impairment

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DAOIB<br>250-1500 mg/day, oral, for 24 weeks | Drug: DAOIB<br> <br> |
| Placebo Comparator: Placebo<br>placebo, oral, for 24 weeks | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24 |  | week 0, 8, 16, 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in speed of processing (Category Fluency) at week 24 |  | week 0, 24 | 
| Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24 |  | week 8, 16, 24 | 
| Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24 |  | week 0, 24 | 
| Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24 |  | week 0, 24 |
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.

Official Title
-----------------
A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy of Omeprazole 20mg and 10mg od for the Four-week Treatment of Non-erosive Reflux Disease (NERD) With That of Placebo od and to Investigate Safety

Conditions
-----------------
Non-erosive Reflux Disease

Intervention / Treatment
-----------------
* Drug: Omeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy. Exclusion Criteria: Patients with any ongoing gastrointestinal bleeding at the time of esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Omeprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the efficacy of omeoprazole 20mg and omeprazole 10mg by assessment of complete resolution rate of heartburn during the fourth week of treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete resolution of heartburn during the first and second week of treatment, assessment of sufficient relief rates of heartburn, assessment of nocturnal heartburn, assessment of other GERD symptoms. |  |  |
Attention and Social Behavior in Children

Study Overview
=================
Brief Summary
-----------------
This study examines the way attention may be linked to temperamental risk for anxiety, social behavior and brain processes. The study aims to see if temperamentally at risk youth display an attention bias towards threat, and if anxiety symptoms can be reduced through attentional bias modification training.

Conditions
-----------------
Anxiety

Intervention / Treatment
-----------------
* Behavioral: Attention Bias Modification
* Behavioral: Dot-probe task


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 9-12 year olds who do not meet exclusionary criteria (split into groups based on high and low temperamental shyness) Exclusion Criteria: presence or permanent metal orthodontics or implanted metal devices severe psychiatric diagnosis IQ under 70 as assessed by the WISC

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ABM<br>Attention bias modification | Behavioral: Attention Bias Modification<br>* This is a modification of the dot-probe task (placebo task) designed to train attention away from threat<br>|
| Placebo Comparator: Placebo<br>Dot-probe task | Behavioral: Dot-probe task<br>* This is the active control placebo condition that simply measures levels of attention to threat<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiety Symptoms | parent and child report of child's anxiety symptoms | 8 weeks | 
| Attention bias levels | performance on computerized attention task | 8 weeks | 
| Electrophysiological and neural correlates of attention bias | EEG and fMRI measures | 8 weeks |
Changes of Soft Tissue Grafting: A Randomized Study

Study Overview
=================
Brief Summary
-----------------
To correct gum recession, patient's own tissue from the roof of the mouth is harvested and placed where there is root exposed. This is considered gold standard of treatment. Sometimes patient don't want to have second surgical site in their mouth and at the same time do not want to use alternative tissue from human or animal donor. Using patients' blood and preparing it as a membrane is the next best thing to correct gum recession.

Detailed Description
-----------------
Patients that are interested in having corrective surgery for recession due to esthetic concerns or sensitivity will be enrolled in the study. The treatment site will randomly receive the procedure assignment. Intraoral scanner will be utilized to establish pre-op volume and will be repeated at each follow up visit. Total of 7visits and 12 mo duration is anticipated for the study.

Official Title
-----------------
Volumetric Changes of Soft Tissue Grafting. Comparison of Autologous PRF (Platelet-rich Fibrin ) & Autogenous CTG (Connective Tissue Grafts) . A Split-mouth Randomized Design

Conditions
-----------------
Gingival Recession

Intervention / Treatment
-----------------
* Procedure: Split Mouth Design


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults 18yrs or older Need of MG-tx for 2 or more sites for root coverage RT I and II (Cairo classification) Class A +/- No class V restoration present Exclusion Criteria: Patients who do not consent to recommended therapy Patients who smoke Patients who will not be able to comply with follow up protocols Those who self report that they are pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All Participants<br>Participants will receive the CTG procedure on one side and the PRF procedure on the other. Both are standard of care soft tissue grafting methods and a split mouth design is standard of care. | Procedure: Split Mouth Design<br>* PRF on one side of mouth and CTG on the other side of participant's mouth.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare autologous PRF & Autogenous CTG | Primary objective of this study is to compare in a split-mouth study the effectiveness of CTG vs. PRF in soft tissue augmentation and volume stability of each treatment modality in correcting the Cairo Class I, II defects in Periodontally affected patients | 12 months |
Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the difference in thrombosis as a result of internal jugular (IJ) catheters versus peripherally inserted central catheter (PICC) lines. It is hypothesized that there will be a decreased rate of thrombosis in patients as a result of IJ catheters verses PICC lines.

Detailed Description
-----------------
In a cohort of patients from Sept 1, 2010 until December 31, 2011 with chronic kidney disease (CKD) has shown that the incidence of IJ thrombosis after short term catheter access occurred in only 1/26 subjects or 4%. The current study is being done to compare this experience with the incidence of thrombosis from PICC lines. A secondary aim will be to determine if variables such as level of renal function, prior history of thrombosis or atherosclerosis contribute to the risk of thrombosis when PICC lines are placed. This data will provide the first comparison of the incidence of thrombotic complications from short term IJ catheter access versus PICC lines.

Official Title
-----------------
Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

Conditions
-----------------
Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects who had a PICC line placed at the University of Chicago between September 1, 2010 and December 31, 2011 Exclusion Criteria: subjects under the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Thrombosis<br>incidence of thrombosis in subjects who had PICC line placement | |
| No Thrombosis<br>no incidence of thrombosis in subjects who had PICC line placement | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Thrombosis | To calculate the incidence of deep venous thrombosis from PICC lines in patients | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic Risk Factor Association with Risk of Thrombosis from PICC or IJ access | To evaluate if factors, known to be associated with thrombosis and atherosclerosis, are associated with the risk of thrombosis from PICC or IJ access. These factors include: renal failure, diabetes, hypertension, cancer, transplant, gender, age or the indication for the access, including antibiotics or chemotherapy. | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thrombosis, Central Venosis Catheter, Renal Disease, Vascular Access
Thrombophylaxis in Transurethral Surgery With Dalteparine

Study Overview
=================
Brief Summary
-----------------
The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40% among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific prophylaxis in patients undergoing transurethral procedures. Our study is the first double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not more complications in transurethral surgery than without.

Detailed Description
-----------------
The aim of our study is to proof that transurethral surgery under thrombophylaxis with dalteparine is safe. The study design is double-blind placebo controlled.

Official Title
-----------------
Thromboseprophylaxe Mit Niedermolekularem Heparin Bei Transurethralen Eingriffen

Conditions
-----------------
Thrombophylaxis in Transurethral Surgery

Intervention / Treatment
-----------------
* Drug: dalteparine (Fragmin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: transurethral surgery Exclusion Criteria: oral anticoagulation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>5000IE dalteparine | Drug: dalteparine (Fragmin)<br>* transurethrals surgery with and without dalteparine<br>* Other names: Dlateparine=Fragmin;|
| Placebo Comparator: B<br>NaCL 0.9% | Drug: dalteparine (Fragmin)<br>* transurethrals surgery with and without dalteparine<br>* Other names: Dlateparine=Fragmin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood loss |  | intraoperativ, 6 hours post op and 3 days postop | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thrombophylaxis and transurethral surgery
Yoga for Treating People at Risk for Diabetes or With Both HIV and Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to plan and develop an international collaboration for research on the health effects of yoga. This study will also determine the effects of yoga on people who are at an increased risk for developing diabetes and people with both HIV and depression.

Detailed Description
-----------------
In recent years, western health practitioners have become increasingly aware of the potential health benefits of yoga. This study will comprise two substudies that will evaluate the effects of yoga in two distinct populations. Participants in the first study will be people who are at risk for developing diabetes; participants in the second study will be people with both HIV and depression. All participants will practice yoga 3 to 6 days per week for 3 months. Blood collection will be done and weight and blood pressure measurements will be taken in study 1 participants; questionnaires will be used to measure depression and stress in study 2 participants. All study participants will be assessed at entry and at 3 and 6 months.

Official Title
-----------------
Yoga, Health, and Meditation

Conditions
-----------------
HIV Infections, Diabetes, Depression

Intervention / Treatment
-----------------
* Behavioral: Yoga


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Study 1 Participants: Meet certain laboratory requirements Inclusion Criteria for Study 2 Participants: HIV infected Able to walk at least 50% of the time Inclusion Criteria for All Participants: Written informed consent of parent/guardian, if applicable Exclusion Criteria for Study 2 Participants: Require antiretroviral therapy

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Yoga|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Yoga, Meditation
Brugada Ablation of VF Substrate Ongoing MultiCenter Registry

Study Overview
=================
Brief Summary
-----------------
Current treatment of high-risk Brugada Syndrome (BrS) patients (pts) with recurrent VF is limited. Catheter ablation (CA) has been performed for BrS but a large study with long-term outcomes of CA in BrS ablation are lacking.

Detailed Description
-----------------
Brugada syndrome (BrS) patients who undergo BRS substrate ablations from tertiary centers for catheter ablations of complex arrhythmias from three continents - Asia, Europe and North America - are registered in a common database. The investigators exclude patients who were lost to follow up in the outpatient clinic.

Official Title
-----------------
Brugada Ablation of VF Substrate Ongoing MultiCenter Registry

Conditions
-----------------
Brugada Syndrome

Intervention / Treatment
-----------------
* Procedure: Catheter Ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic Brugada Syndrome patients who had undergone catheter ablation of the arrhythmogenic substrates. Exclusion Criteria: Patients who will not commit to regular follow up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CA BrS<br>Symptomatic BrS patients who underwent catheter ablation of the BrS/VF substrate | Procedure: Catheter Ablation<br>* Ventricular fibrillation substrate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | Expiration, unrelated to procedure | 3 years | 
| ICD Therapy for VT/VF | Electrical therapy delivered through device for termination of VF episodes | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inappropriate ICD Therapy | Caused by lead sensing or programming errors | 3 years | 
| Normalization of Brugada ECG pattern | ECG pattern is normal sinus rhythm after catheter ablation | 3 years |